American Journal of Transplantation的动态

#Proposed Title:** A Comprehensive Review of #Liver #Diseases and #Liver #Cancer in the Asia Pacific Region #Abstract:** The Asia Pacific region faces a disproportionate burden of liver diseases and liver cancer, driven by complex factors including viral hepatitis, alcohol consumption, and non-alcoholic fatty liver disease. This review aims to provide a comprehensive overview of the epidemiology, risk factors, prevention strategies, and treatment options for these pressing health challenges. We will delve into the specificities of liver diseases in the region, including the prevalence and impact of hepatitis B and C, alcohol-related liver disease, and non-alcoholic steatohepatitis. Additionally, we will explore the growing incidence of liver cancer and discuss the latest advancements in diagnosis, treatment, and survivorship. By highlighting the unique challenges and opportunities faced by the Asia Pacific region, this review seeks to inform healthcare professionals, policymakers, and researchers, and to catalyze collaborative efforts to improve liver health and reduce the associated mortality. #liver #diseases, #liver #cancer, #Asia #Pacific, #hepatitis, #alcohol, #non-#alcoholic #fatty #liver #disease, #prevention, #treatment

?? Breaking News Alert! ?? ?? Ready to revolutionize the way we assess and predict liver-related events in metabolic dysfunction–associated steatotic liver disease (MASLD)? Look no further than the latest groundbreaking research hot off the press from JAMA! ?? ?? "Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease" unveils a game-changing approach to assessing disease severity and prognosis in MASLD. ?? ?? This cohort study, spanning over 16,000 patients across 16 tertiary referral centers worldwide, introduces the Agile scores—Agile 3+ and Agile 4—as powerful predictors of liver-related events. From hepatocellular carcinoma to hepatic decompensation, these scores are on the money! ?? ?? But here's the kicker: these VCTE-based scores outshine most noninvasive tests and even rival histologic fibrosis staging in their predictive prowess. Talk about a game-changer in routine clinical practice and clinical trials for steatohepatitis! ?? ?? And the excitement doesn't stop there! With serial measurements, these scores prove to be consistent and stable, offering clinicians a reliable tool for monitoring patient progress and predicting outcomes. ?? ?? The clinical implications are crystal clear: VCTE-based scores are here to stay, offering accurate predictions and sparing patients the invasive nature of liver biopsy. It's a win-win for clinicians and patients alike! ?? ?? Ready to dive deeper into the future of MASLD assessment? Don't miss out on this groundbreaking research—it's a game-changer in hepatology! ?? ?? https://lnkd.in/gcc3K6Yv #Hepatology #LiverDisease #MedicalResearch #VCTE #JAMA #GroundbreakingResearch

Acute liver failure is a rare condition with a high mortality unless liver transplantation is performed. It is particularly important to improve the outcome in LMICs. International collaboration is needed, starting with the establishment of central registries. https://lnkd.in/dxrPUnnW #Hepatology?#ViralHepatitis?#AcuteLiverFailure?#WorldLiverDay

We are excited to announce that the American Journal of Gastroenterology has published results from our 240-patient pivotal clinical validation study which demonstrated that patients with Barrett’s esophagus (BE), identified by Esopredict as having high risk had an average risk of progression of 22% within five years, 4x more likely than the average risk based on prevalence to progress to high grade dysplasia or esophageal adenocarcinoma, while those identified as low-risk patients reflected only a 1.9% risk, with a modeled negative predictive value of 99%. Esopredict is a first-in-class offering and is the only epigenetic, prognostic assay designed to predict the likelihood of a patient with Barrett’s esophagus progressing to either HGD or EAC within five years. “This important milestone would not have been possible without the hard work, dedication, and innovative spirit of the entire Previse team. We are excited about Esopredict's timing and ability to change the paradigm in BE surveillance and treatment, as esophageal cancer rates have continued to climb and claim more lives each year."- Daniel Lunz, Chief Executive Officer and Co-Founder of Previse. Learn more about Esopredict and Previse at https://previsedx.com/ #barrettsesophagus #gastroenterology #innovation #gihealthcare https://lnkd.in/grR5z4vf

Transforming Liver Disease Research with Spatial Genomics Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a leading cause of chronic liver disease globally. Its progression to?metabolic dysfunction-associated steatohepatitis (MASH)?can lead to severe complications, including cirrhosis and hepatocellular carcinoma. ?? The Game-Changer: Spatial Genomics?Recent technological advancements, such as?single-cell and single-nuclei RNA sequencing, have revolutionized our understanding of liver biology in health and disease. However, the next critical step is?spatial genomics—the ability to contextualize single-cell information in its native environment. ?? Why Is This Important??Spatial genomics is balanced to: - Provide a deeper understanding of liver biology and the progression of MASLD/MASH. - Help identify new?therapeutic targets?for liver disease. -Accelerate breakthroughs in?precision medicine?for patients with chronic liver conditions. The innovative research has the potential to revolutionize our understanding of hepatology, opening doors to groundbreaking treatments and significantly enhancing the prognosis for the millions of people impacted by liver diseases globally. Read the full article in Nature Reviews Gastroenterology & Hepatology https://lnkd.in/egCidiW9 #MASLD #Hepatology #SpatialGenomics #LiverDisease #PrecisionMedicine #HealthcareInnovation #ResearchAndDevelopment #Biotechnology

???????????????? ?????????? ??????????: ???????????????????? ???????????????????? ?????????????? ???? ?????????? ???????????? ?????????????? ?????????? Dr. Celia Martinez-Jimenez (Celia M.)?& team at #HelmholtzMunich reveal how #LiverCell polyploidy slows #aging & maintains homeostasis. While traditionally viewed as a terminal-differentiated cellular state, this study published in?Journal of Hepatology uncovers a previously unexpected adaptive role of hepatocyte polyploidization in response to genomic perturbation and aging. The genomic shield appears to enrich for wild-type alleles during aging, presenting a novel perspective on liver health and potential therapeutic avenues in addressing aging-related diseases such as non-alcoholic fatty liver disease, cirrhosis, and hepatocellular carcinoma. ?? Learn more in our news: https://lnkd.in/dXZeWZ9k Helmholtz Pioneer Campus @ Helmholtz Munich #carcinoma #liver #therapy #research #aging

Exciting new developments on the horizon for patients with #NASH?#MASH?#FattyLiver?#NAFLD #gastroenterology?#hepatology?#SydneyGastroenterologyAndLiverGroup This disease is becoming vastly more prevalent and will be leading indicator for liver transplant now that viral hepatitis can be managed. No great treatments available, we need safe and viable options. This article reported resolution of #MASH in the Tirzepatide group without any progression of fibrosis. Key take home is to start treatment early in this cohort of patients.

A world-first research discovery from the Storr Liver Centre at WIMR has identified why lean people with metabolic dysfunction-associated fatty liver disease (MAFLD) have higher mortality than their non-lean counterparts. The research finding provides a new drug target for the development of potentially lifesaving treatments, as well as the potential to increase early detection. MAFLD affects up to one third of the global population and is the leading cause of end-stage liver disease, liver cancer and liver transplantation. In Australia, the prevalence of MAFLD has been reported to be 20-30% and is the most common liver disease. Although typically associated with excess weight, obesity and type 2 diabetes, up to 20% of individuals with MAFLD are considered to be lean. Sydney University PhD student Mohammad Alarabi is first author of the study, published in Hepatology International. He says, “Despite being healthier overall than their overweight or obese counterparts, lean people with MAFLD have a worse long-term prognosis. We set out to understand the mechanisms that cause this seemingly contradictory outcome.” Read more here: https://lnkd.in/ggcrFGNk Hepatology International

?????????????????????????? ?????????????????????????? ???? ???? ????????-???????????????????????? ?????????????????? ?????????????????? ???????? ?????????????????? ?????????????????? ???? ?????? ???????????????????? ???? ???????????????? ???????? ?????????????????? ?????????? ?????????????? ?? Non-alcoholic fatty liver disease (#NAFLD) affects a substantial proportion of the adult population in high-income countries and has become a leading indication for liver transplantation. The gut microbiota dysbiosis has been firmly established as a contributing factor to NAFLD. In this study, researchers investigated the association between gut microbiota composition and NAFLD severity, focusing on the depletion of ?????????????????????????? ???????????????????????????in patients with liver diseases. ?? Key Scientific Findings ?? Decreased Abundance of ??. ?????????????????????????? in NAFLD/NASH Patients: -??. ???????????????????????????was depleted in patients with liver diseases such as NAFLD/NASH compared to healthy controls. -The abundance of ??. ?????????????????????????? decreased as the disease progressed, suggesting a strong association with disease severity. -Similar to other key protective bacteria in different pathologies, such as ???????????????????????????????? ?????????????????????? ?????? ?????????????????????? ??????????????????????, ??. ?????????????????????????? played a crucial protective role in maintaining gut health. ?? ??. ?????????????????????????? Presence in Human Gut: -Genomic analysis revealed that ??. ?????????????????????????? strains are closely related, and the existence of subspecies is not supported by extensive genome comparison. -While originally named for its equol production capacity, most strains of ??. ?????????????????????????? lack the equol production pathway, suggesting other metabolic functionalities may be significant. - ??. ?????????????????????????? depleted not only in liver diseases but also in other pathologies, including ulcerative colitis. ?? ??. ?????????????????????????? Presents Anti-Inflammatory Properties: -In vitro experiments demonstrated that ??. ?????????????????????????? possesses anti-inflammatory properties by inhibiting the NF-κB pathway in intestinal epithelial cells and hepatocytes. -The anti-inflammatory effect is not attributed to short-chain fatty acid production, as ?????????????????????????? ?????????????????????????? does not produce butyrate or propionate. -In vivo mouse experiments showed reduced weight gain and improved glycemia in mice administered ?????????????????????????? ?????????????????????????? accompanied by lower expression of inflammatory markers. EXPLORE THE STUDY : https://lnkd.in/gbD3AjAq #guthealth #gutliveraxis #liverdisease #liverdysfunction #gutmicrobiome #dysbiosis #healthygut #metabolicdisease #microvioma Maneesh Paul. S., Ph.D., Florian Plaza O?ate ,Célia Chamignon, Sebastian D. Burz, Nicolas Lapaque, Magali Monnoye

B.C. is spearheading a world-first project to better match donor organs to kidney recipients. This could be a gamechanger, resulting in less rejection, better outcomes, and potentially an end to lifelong antirejection medication for transplant patients. Led by Dr. Paul Keown, a specialist in immunology and transplant and professor at UBC, Dr. James Lan, a transplant nephrologist and Medical Director of the Immunology Laboratory at Vancouver General Hospital, the new method using epitopes will be implemented in Vancouver and extended across Canada. The team was recently awarded $5.8 million from Genome BC, Genome Canada, Michael Smith Health Research BC, and others. BC Transplant is also supporting this project. The team will focus on kidneys first and then extend the benefits to patients awaiting other organs. “One out of three transplanted kidneys will stop functioning after 10 years, and then it’s back to dialysis or another kidney transplant for those patients,” explains Dr. Lan. “Half of those failed kidneys are due to rejection. We can all agree this is not optimal, and we have been trying to find a way to revolutionize transplants to overcome this problem since 2010.” Dr. Keown adds, “We think this new way to match organs will be truly transformative. Five or 10 years from now, I believe we will be able to transplant patients safely and successfully, knowing that many of them will keep their new kidney, or eventually their new heart, or new lungs, with minimal immunosuppression for the rest of their life.” Read more: https://lnkd.in/gCQphsXz Michael Smith Health Research BC Vancouver Coastal Health The University of British Columbia UBC Department of Medicine Genome Canada Genome British Columbia VCH Research Institute Paul Keown